Literature DB >> 8700878

Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease.

S K Ray1, C Putterman, B Diamond.   

Abstract

The immune system's ability to distinguish self and nonself is essential for both host defense against foreign agents and protection of self-antigens from autoimmune destruction. Such discrimination is complicated by extensive structural homology shared between foreign and self antigens. One hypothesis to explain the development of an autoimmune response is that some B cells activated by foreign antigen acquire, through somatic mutation, specificity for both the eliciting foreign antigen and self antigen. If such clones arise frequently, there must be a mechanism for their elimination. We have analyzed the extent of autoreactivity arising in a nonautoimmune host during the response to a foreign antigen. To overcome the process of apoptosis in primary B cells that might routinely eliminate autoreactive clones, we generated B-cell hybridomas from spleen cells of immunized mice by using a fusion partner constitutively expressing bcl-2. Multiple lines were obtained that recognize simultaneously the hapten phosphorylcholine and the self antigen double-stranded DNA. This dual specificity was not present early but was detected by day 10 after immunization. Some of these cross-reactive antibodies deposit in kidneys in a pattern similar to what is seen in autoimmune disease. These results demonstrate that autoantibodies arise at a high frequency as part of a response to foreign antigen. It has previously been shown that autoreactivity is regulated by central deletion; these data demonstrate a need for negative selection in peripheral lymphoid organs also, to regulate autoantibodies acquiring their self-specificity by somatic mutation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8700878      PMCID: PMC39902          DOI: 10.1073/pnas.93.5.2019

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Comparative study of NZB mice under germfree and conventional conditions.

Authors:  K K Unni; K E Holley; F C McDuffie; J L Titus
Journal:  J Rheumatol       Date:  1975-03       Impact factor: 4.666

2.  Cross-reactive antibodies have both protective and pathogenic potential.

Authors:  W Limpanasithikul; S Ray; B Diamond
Journal:  J Immunol       Date:  1995-07-15       Impact factor: 5.422

3.  Antigen-induced B-cell death and elimination during germinal-centre immune responses.

Authors:  K M Shokat; C C Goodnow
Journal:  Nature       Date:  1995-05-25       Impact factor: 49.962

4.  Soluble antigen can cause enhanced apoptosis of germinal-centre B cells.

Authors:  B Pulendran; G Kannourakis; S Nouri; K G Smith; G J Nossal
Journal:  Nature       Date:  1995-05-25       Impact factor: 49.962

5.  Generation of a fusion partner to sample the repertoire of splenic B cells destined for apoptosis.

Authors:  S Ray; B Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

Review 6.  Biology of germinal centers in lymphoid tissue.

Authors:  G J Thorbecke; A R Amin; V K Tsiagbe
Journal:  FASEB J       Date:  1994-08       Impact factor: 5.191

7.  A single VH gene segment encodes the immune response to phosphorylcholine: somatic mutation is correlated with the class of the antibody.

Authors:  S Crews; J Griffin; H Huang; K Calame; L Hood
Journal:  Cell       Date:  1981-07       Impact factor: 41.582

8.  Dysregulation of the humoral immune response in old mice.

Authors:  K S Zhao; Y F Wang; R Guéret; M E Weksler
Journal:  Int Immunol       Date:  1995-06       Impact factor: 4.823

9.  Mutational analysis of an autoantibody: differential binding and pathogenicity.

Authors:  J B Katz; W Limpanasithikul; B Diamond
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

10.  Clonal nature of the immune response to phosphorylcholine. I. Specificity, class, and idiotype of phosphorylcholine-binding receptors on lymphoid cells.

Authors:  J L Claflin; R Lieberman; J M Davie
Journal:  J Exp Med       Date:  1974-01-01       Impact factor: 14.307

View more
  65 in total

Review 1.  Maintenance and loss of self-tolerance in B cells.

Authors:  A Iglesias
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 2.  Somatic hypermutation in human B cell subsets.

Authors:  N S Longo; P E Lipsky
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 3.  A model for lupus brain disease.

Authors:  Betty Diamond; Bruce T Volpe
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

4.  Hormonal milieu at time of B cell activation controls duration of autoantibody response.

Authors:  Venkatesh Jeganathan; Elena Peeva; Betty Diamond
Journal:  J Autoimmun       Date:  2014-03-28       Impact factor: 7.094

5.  Experimental lupus nephritis in severe combined immunodeficient (SCID) mice: remodelling of the glomerular lesions by bystander IgM antibodies.

Authors:  M R Ito; S Terasaki; E Kondo; H Shiwaku; Y Fukuoka; M Nose
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 6.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

Review 7.  T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens.

Authors:  Syamal K Datta; Li Zhang; Luting Xu
Journal:  J Mol Med (Berl)       Date:  2005-01-04       Impact factor: 4.599

8.  Receptor editing in peripheral B cell tolerance.

Authors:  Jeffrey S Rice; Jeffrey Newman; Chuansheng Wang; Daniel J Michael; Betty Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-19       Impact factor: 11.205

9.  Immunoglobulin kappa chain receptor editing in systemic lupus erythematosus.

Authors:  T Dörner; S J Foster; N L Farner; P E Lipsky
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

10.  Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease.

Authors:  H E Baxendale; M Johnson; R C M Stephens; J Yuste; N Klein; J S Brown; D Goldblatt
Journal:  Clin Exp Immunol       Date:  2007-11-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.